1Y Close · As of Aug 26, 2026
ORIENTBIO operates in the Pharmaceuticals sector.
Legal name: ORIENTBIO Inc.
In fiscal year 2021, ORIENTBIO (002630) reported revenue of 52.0 billion KRW, up 39.8% from 37.2 billion KRW a year earlier.
Operating profit was 1.9 billion KRW and net income was -15.6 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 54.7 billion KRW, with a P/B of 0.76.
These figures can be verified in the DART filing (receipt no. 20250619000265).
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Quarterly Report (2026.06) |
| 2026-08-03 | Extraordinary Meeting Result |